Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Q1 2024 Ends in almost 2 business weeks...
View:
Post by anabelsi on Mar 14, 2024 7:52pm

Q1 2024 Ends in almost 2 business weeks...

...and yet, we have heard nothing about pre-BTD so far!

Did pre-BTD get pushed out? I recall seeing that they delayed the BTD application to Q2, but pre-BTD was supposed to be in Q1 as far as I recall.
Comment by O12009 on Mar 14, 2024 8:10pm
It would be nice to get an update on this , even though a lot of knowledgeable people on here say that is not a normal occurrence. As we all know this trial ran right through the middle of Covid so normal is by far out of the question.
Comment by judgesmails on Mar 14, 2024 11:32pm
Yes.  Pre BTD submission was definitely planned for Q1 and...assuming it is accepted, BTD is supposed to be prepared within 3 weeks and submitted later in Q1 or early Q2 for approval sometime later in Q2.  Anticipated timeline is approx 2 months from BTD submission to approval. However; no updates on anything so far in 2024.  So who knows if pre BTD is submitted and is simply not ...more  
Comment by Legit62 on Mar 15, 2024 7:01am
To be honest judgesmails, we not hear anything until BTD accepted, just my opinion, we may get some updated data though, but , just reasoning from previous PRs, pretty secretive till after the fact here, any thoughts??
Comment by Alamir1111 on Mar 15, 2024 9:12am
37 patients to be treated at 11css's by end 2024.interesting to see the nr of patients recruited in next uptade.
Comment by Oilminerdeluxe on Mar 15, 2024 9:21am
I am not sure any new ones have been treated. Guess we will have to wait and see. Those updates are always welcome.
Comment by Alamir1111 on Mar 15, 2024 9:35am
Wonder how much it costs tlt  for each patient from recruiting 2 treatments tests etc till end of study?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250